This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Allergan opposes class certification for end payors in Restasis case

( October 10, 2019, 22:31 GMT | Official Statement) -- MLex Summary: Allergan filed an opposition to end-payor plaintiffs’ motion for class certification in a case accusing the company of delaying a generic version of the drug Restasis. Allergan says several unique aspects of the case “guarantee that numerous consumers and third-party payors that would not have been harmed by alleged delays in generic entry are impermissibly part of the putative class and make it impossible to identify and exclude such class members absent a highly individualized inquiry.”See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections